231 Front Street, Lahaina, HI 96761 info@givingpress.com 808.123.4567

Tag: Precision

Dentist Fortitude Valley, Precision Dental, Offers General and Cosmetic Dentistry Solutions in a Caring and Friendly Environment in QLD – Press Release

Dentist Fortitude Valley, Precision Dental, Offers General and Cosmetic Dentistry Solutions in a Caring and Friendly Environment in QLD

Fortitude Valley, QLD – Not every dentist is the same. There are those that will only be concerned about providing treatment while there are others that will go above and beyond in ensuring that patients are feeling comfortable. Precision Dental is a modern dental practice that is based at the heart of Brisbane servicing Fortitude Valley and is committed to high-quality dental care. The practice provides both general and cosmetic dental treatment for the whole family.

“Our ultra-modern practice is conveniently located in HQ Towers which offer free onsite parking for the duration of treatment. Emergency appointments are available throughout the day and Saturday appointments can be arranged. We are equipped with the latest generation of equipment and pride ourselves in providing thorough dental treatment that is tailored to individual needs and goals.” Said Dr Billy Choi, the spokesperson for the clinic, regarding their unrivalled services.

The dental practice was founded on three key principles including honesty, patient comfort, and quality. Every member of the staff will ensure that patients are comfortable right from the moment they walk in their office. The clinic uses the latest generation of quiet equipment to ensure that dental visits are enjoyable. Some of the tools that can be found in the treatment room to make patients relax include:


Parents can rest easy knowing that the clinic offers children’s dental emergency treatments. Children have high energy and are always going to be susceptible to dental emergencies. The dentists have knowledge in dealing with such unexpected events and will ensure that children are not experiencing discomfort a minute longer. The practice applies advanced skills in dentistry and state-of-the-art equipment to overcome dental emergencies.

The clinic also aims at being the leading cosmetic dentistry treatment provider in Fortitude Valley, one smile at a time. The treatment options are tailored to meet the individual needs of the patient. A good dentist Fortitude Valley is one that will start by assessing the individual needs of the patient before coming up with a course of action and this is exactly what you get when you reach out to Precision Dental. Getting a smile makeover will help in maintaining a youthful appearance and also boosts the self-confidence of a person. Patients can enjoy all of these benefits by booking a dental appointment with Precision Dental at their own convenient time.

The clinic also believes in providing education to patients because good dental care requires a holistic approach. The clinic believes that a dentist should be a partner when it comes to the wellbeing of the teeth, gums, and mouth. Precision Dental provides patients with both basic and advanced information so that they’re establishing a consistent and reliable oral care routine. It is also easy for patients to book an appointment when they visit their website.

Precision Dental is located at S13, HQ South Tower, 520 Wickham St, Fortitude Valley, QLD 4006. For enquiries regarding the top-rated dentist Fortitude Valley and the services offered, contact their team by calling (07) 3852 1160

Summa Equity Acquires Sengenics to Advance Precision Medicine Through Proteomics

Summa Equity, the purpose-driven private equity firm that invests to solve global challenges, has acquired a majority stake in Sengenics, a functional proteomics company with a proprietary technology called KREX that enables researchers to vastly improve the understanding of the human proteome and immune system. Proteomics, i.e. the large-scale study of proteins, is one of the most important areas for gaining insights into human biology and disease, as protein expressions, structures and functions are critical in reflecting states of health.

Sengenics was first founded in 2008 and went on to commercialise the KREX technology that was originally developed from a joint collaboration between the University of Cambridge and the University of Oxford. The company’s patented KREX technology enables researchers to address both the function and folding structure of proteins using one technology that allows for large numbers of proteins to be studied simultaneously, with high sensitivity and specificity. The combination of these capabilities makes KREX unique. The technology is relevant for a broad range of applications in research and throughout the value chain for drugs, vaccines and diagnostics. Sengenics is currently mainly focused on autoantibody detection for applications in autoimmune diseases, oncology and infectious diseases, including COVID-19. The company recently launched a unique high-throughput, multi-antigen, multi-domain and fully quantitative COVID-19 test, leveraging the KREX technology.

Sengenics has grown rapidly in recent years and established customer relationships with top global pharmaceutical companies, and leading research and academic institutions around the world. The company currently has commercial partnerships with 9 out of the top 10 pharmaceutical companies to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs. Sengenics is based in Europe and South-East Asia.

“Sengenics’ proprietary technology unlocks tremendous potential for researchers around the world to further their understanding of biology and disease,” says Tommi Unkuri, Partner at Summa Equity. “We are proud to partner with the company and support its journey, as it looks to expand its position in the market and grow its business. We look forward to supporting the Sengenics team in our shared ambition to invest to drive product development, global expansion and accelerated adoption.”

Summa Equity invests in companies that address global challenges, while managing environmental, social, and governance (ESG) factors, with the aim of increasing returns and reducing risk. It was the first company to align its investments with the UN Sustainable Development Goals. The investment in Sengenics is aligned with the firm’s Changing Demographics theme and supports the SDG Target #3: “Ensure healthy lives and promote well-being for all at all ages”, by enabling improved diagnosis, treatment and patient outcomes across a number of disease areas.

“We are excited to welcome Summa Equity as a major strategic investor and shareholder in Sengenics. Their extensive capabilities and alignment with our vision of changing the future of medicine through immune-proteomics is a very strong strategic fit. Summa also has a great deal of relevant knowledge and experience to be a value-added owner for us given its ownership of Olink Proteomics. This

SEngine Precision Medicine to Present at Society of Functional Precision Medicine Virtual …

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) — SEnginePrecision Medicine, a precision oncology company revolutionizing cancer diagnostics and drug discovery by pre-testing drugs on patient-derived tumor organoids, today announced that Chief Medical Officer Astrid L. Margossian, MD, PhD, will present at the Society for Functional Precision Medicine (SFPM) Virtual Monthly Seminar on October 14th at 11:30 am ET.

Dr. Margossian is leading SEngine’s clinical validation initiatives for the PARIS® Test, a CLIA certified cancer organoid based drug sensitivity test for all solid tumors. The presentation is entitled, “Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test,” and will highlight the data on the PARIS® Test, recently presented at the ASCO 2020 and ACCR 2020 annual meetings, inclusive of organoids sensitivity results, showing clinical correlation with genomics and previous clinical treatments. Registration for the live event is available for free at https://www.sfpm.io/seminars.php.

SFPM’s virtual monthly seminar brings together distinguished guest speakers and through interactive panel discussions and Q&A sessions focuses on these key topics:

  • Demonstrating the clinical utility of functional precision medicine testing
  • Implementing functional testing in precision medicine clinical trials
  • Accelerating the application of functional testing
  • Addressing stakeholder, educational and investment challenges for functional precision medicine

About PARIS® Test
The CLIA certified PARIS® Test is based on the capability to propagate patient-specific cancer tissue as organoids ex vivo and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics. For cancers where the path is not clear, such as many metastatic and recurrent cancers, the PARIS test provides crucial information to the treating physicians to match the right drug to the right patient.

About SEngine Precision Medicine
SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells. As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializing the PARIS® Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine’s CLIA certified PARIS® Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more at SengineMedicine.com and follow the latest news from SEngine on Twitter at @SEngineMedicine and on LinkedIn.

Contact:
Stephanie Carrington
stephanie.carrington@westwicke.com
646-277-1282

Source Article